trending Market Intelligence /marketintelligence/en/news-insights/trending/phgShYB-w40o0VWbKZc2gg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Adamis seeks US FDA approval for higher dose of opioid overdose therapy

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Adamis seeks US FDA approval for higher dose of opioid overdose therapy

Adamis Pharmaceuticals Corp. said the U.S. Food and Drug Administration accepted for review its application for a higher dose of naloxone to treat opioid overdose.

The company's new drug application covers an injectable version of the medicine. The agency is expected to make a decision by Oct. 31.

Naloxone works by blocking or reversing the effects of opioids, such as extreme drowsiness, slowed breathing or loss of consciousness. A nasal spray version of the drug is marketed by Adapt Pharma Operations Ltd. under the Narcan brand. Meanwhile, kaleo Inc. offers Evzio, an autoinjectable version of the opioid overdose therapy.

San Diego-based Adamis Pharmaceuticals develops and sells products for various therapeutic areas, including respiratory disease and allergy.